EU's "Horizon 2020" to fund innovative drug/diagnostic R&D and boost life sciences industry
This article was originally published in Scrip
The European Parliament has given the go-ahead to "Horizon 2020", the EU's most ambitious research and innovation program to date. With a budget of almost €80bn over seven years, the program includes public-private partnerships in areas such as novel medicines, biomarkers and diagnostics.
You may also be interested in...
As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.
New advice on the use of "mix-and-match" primary and booster vaccine regimens has been published by the EMA and the ECDC, while a new CEPI-supported clinical trial will test heterologous booster combinations involving Medigen’s COVID-19 vaccine and other jabs.
Coronavirus Notebook: EMA OKs Roche's Tocilizumab For Severe COVID-19, Bavarian Nordic Reports ‘Positive’ Booster Results
The European Commission is to replace its COVID-19 vaccine export authorization system with a monitoring scheme, and the European Medicines Agency has confirmed the risk of myocarditis and pericarditis with the mRNA vaccines. The WHO and other bodies have called for better vaccine donation practices in Africa.